ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Up 74.3% in August

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) was the target of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 78,401 shares, an increase of 74.3% from the July 30th total of 44,970 shares. Currently, 2.5% of the company’s shares are short sold. Based on an average daily trading volume, of 37,830 shares, the short-interest ratio is currently 2.1 days.

ALPS Medical Breakthroughs ETF Price Performance

Shares of SBIO opened at $66.86 on Wednesday. ALPS Medical Breakthroughs ETF has a 52-week low of $34.88 and a 52-week high of $70.85. The business’s 50 day moving average price is $66.02 and its two-hundred day moving average price is $57.39.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in ALPS Medical Breakthroughs ETF by 63.1% during the first quarter. Bank of America Corp DE now owns 98,679 shares of the company’s stock worth $5,165,000 after purchasing an additional 38,193 shares during the last quarter. Moran Wealth Management LLC grew its position in shares of ALPS Medical Breakthroughs ETF by 39.2% during the 1st quarter. Moran Wealth Management LLC now owns 29,348 shares of the company’s stock valued at $1,536,000 after acquiring an additional 8,264 shares during the period. Steward Partners Investment Advisory LLC bought a new position in shares of ALPS Medical Breakthroughs ETF during the 4th quarter valued at approximately $26,000. Fulcrum Equity Management purchased a new stake in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter worth approximately $263,000. Finally, Harbor Investment Advisory LLC purchased a new stake in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter worth approximately $29,000.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.